Pathophysiology
- Decreased production: Bone marrow failure conditions (aplastic anemia, myelodysplastic syndromes, leukemia) suppress or crowd out megakaryocytes — the platelet-producing cells. Chemotherapy, radiation therapy, and alcohol toxicity also suppress marrow. B12 and folate deficiency impair megakaryocyte maturation.
- Increased destruction: The most common acquired cause is immune thrombocytopenic purpura (ITP) — autoantibodies (usually IgG) coat platelets, marking them for premature destruction by splenic macrophages. Platelet lifespan drops from 8–10 days to hours. Heparin-induced thrombocytopenia (HIT) is a paradoxical condition where heparin triggers antibodies that activate platelets, simultaneously causing thrombocytopenia and life-threatening thrombosis. Disseminated intravascular coagulation (DIC) consumes both platelets and clotting factors in widespread microvascular clotting. Thrombotic thrombocytopenic purpura (TTP) causes platelet consumption in microthrombi, producing the classic pentad: thrombocytopenia, microangiopathic hemolytic anemia, neurological symptoms, renal impairment, and fever.
- Sequestration: Hypersplenism (enlarged spleen from liver disease, portal hypertension, or hematologic malignancy) traps platelets — up to 90% of the circulating supply — removing them from effective circulation.
- Dilutional: Massive transfusion of packed RBCs without concurrent platelet replacement dilutes the existing platelet pool.
- Clinical bleeding risk correlates with count: 50,000–150,000/mcL — mild, often asymptomatic. 20,000–50,000/mcL — increased mucocutaneous bleeding with minor trauma. < 20,000/mcL — risk of spontaneous bleeding including intracranial hemorrhage. < 10,000/mcL — life-threatening spontaneous hemorrhage.
Signs and Symptoms
- Petechiae: Pinpoint (1–2 mm) red-purple spots, typically on the trunk and lower extremities, caused by capillary bleeding into the skin. Do not blanch with pressure. The hallmark visible sign.
- Purpura: Larger purple patches (> 3 mm) from subcutaneous hemorrhage
- Ecchymoses: Extensive bruising from minimal or no apparent trauma
- Mucosal bleeding: Epistaxis (nosebleeds), gingival bleeding, GI bleeding (melena, hematemesis)
- Menorrhagia: Heavy menstrual bleeding — may be the presenting complaint
- Prolonged bleeding from minor cuts or venipuncture sites
- Hematuria (blood in urine)
- In severe cases (< 10,000/mcL): risk of intracranial hemorrhage — sudden severe headache, altered consciousness, neurological deficit
Red Flags
- Sudden severe headache, visual changes, altered consciousness, or new neurological symptoms in a thrombocytopenic client — possible intracranial hemorrhage. Call 911 immediately
- Active, uncontrolled bleeding from any site. Urgent medical referral
- New petechiae or expanding bruising appearing during the massage session — stop treatment immediately and refer
- Platelet count < 20,000/mcL — massage is generally contraindicated due to spontaneous bleeding risk
Massage Therapy Considerations
- Platelet count is the decision-making guide:
- 50,000–150,000/mcL: Light to moderate pressure; avoid deep tissue, vigorous friction, and cupping
- 20,000–50,000/mcL: Very light pressure only; avoid any technique that could cause bruising; gentle holding, light effleurage, energy work
- < 20,000/mcL: Massage is generally contraindicated — spontaneous bleeding risk is too high
- Coordinate with the physician: Request current platelet count before each treatment session. Platelet counts can fluctuate rapidly, especially in ITP and during chemotherapy cycles.
- Monitor during treatment: Inspect the skin before and during the session for new petechiae, expanding bruises, or unexpected bleeding. Stop immediately if new bleeding signs appear.
- Gentle relaxation massage is indicated when counts permit: Stress reduction and quality of life improvement are meaningful therapeutic goals for clients with chronic thrombocytopenia, particularly those undergoing cancer treatment.
- Avoid percussion, deep friction, vigorous effleurage, cupping, and guasha — all can cause subcutaneous hemorrhage at low platelet counts.
- Avoid IM injections, acupuncture, and dry needling in thrombocytopenic clients — prolonged bleeding from puncture sites.
- Infection control: Clients with thrombocytopenia secondary to bone marrow failure (leukemia, aplastic anemia, chemotherapy) are often concurrently immunocompromised. Strict hygiene. Reschedule if the therapist is ill.
- Medication awareness: Clients with ITP may be on corticosteroids (skin fragility, easy bruising) or immunosuppressants (infection risk). Clients with HIT are on alternative anticoagulants (argatroban, fondaparinux) — anticoagulated clients require additional pressure reduction.
CMTO Exam Relevance
- Category A7 — Systemic Conditions (Hematologic)
- Thrombocytopenia classification: decreased production (marrow failure), increased destruction (ITP, HIT, DIC, TTP), sequestration (hypersplenism), dilutional — a testable classification framework
- Petechiae, purpura, and ecchymoses are the hallmark triad of signs — know their size distinctions and clinical significance
- Platelet count thresholds for MT decision-making are testable clinical reasoning
- ITP (most common acquired cause) and HIT (paradoxical thrombosis despite low platelets) are high-yield exam conditions
- Know that thrombocytopenia affects primary hemostasis (platelet plug formation) while hemophilia affects secondary hemostasis (fibrin reinforcement) — different mechanisms, different bleeding patterns
Key Takeaways
- Thrombocytopenia means low platelets (< 150,000/mcL), impairing the body's ability to form platelet plugs during primary hemostasis
- Massage pressure must be guided by platelet count: light-to-moderate above 50,000, very light between 20,000–50,000, contraindicated below 20,000
- Petechiae (pinpoint red-purple spots that do not blanch) are the hallmark visible sign. New petechiae during treatment means stop immediately
- Always coordinate with the physician for current lab values before treating — platelet counts can fluctuate rapidly
- Causes include decreased production (chemotherapy, marrow failure), increased destruction (ITP, HIT, DIC), and sequestration (hypersplenism)
- Clients with concurrent immunosuppression require strict infection control measures
- HIT is a dangerous paradox — thrombocytopenia with simultaneous thrombosis risk — know that low platelets do not always mean bleeding risk alone